Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DBH | P09172 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3159524 | 0.82 | CHRNB2 (0.39) | DBHALDH1A1POLBKMT2AATM | |
| SCHEMBL11079680 | 0.69 | DBH (1.00) | DBHALDH1A1POLBKMT2AATM | |
| SCHEMBL3165838 | 0.69 | LPO (0.40) | ALDH1A1TSHRCYP1A2SMN1; SMN2 | |
| SCHEMBL3179003 | 0.69 | RAB9A (0.49) | ALDH1A1KMT2AATMHPGDSMN1; SMN2 | |
| SCHEMBL3169016 | 0.66 | ALDH1A1 (0.50) | DBHALDH1A1KMT2ATSHRHPGD | |
| SCHEMBL945487 | 0.66 | ALDH1A1 (0.47) | ALDH1A1KMT2ATSHRSMN1; SMN2 | |
| SCHEMBL27882191 | 0.66 | ALDH1A1 (0.43) | ALDH1A1KMT2AL3MBTL1TSHRHPGD | |
| SCHEMBL27792150 | 0.65 | TSHR (0.50) | ALDH1A1KMT2AL3MBTL1TSHRCYP1A2 | |
| SCHEMBL8151927 | 0.64 | SMN1; SMN2 (0.54) | ALDH1A1TSHRCYP3A4HPGDSMN1; SMN2 | |
| SCHEMBL4912652 | 0.64 | IDO1 (0.42) | ALDH1A1POLBL3MBTL1TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100010049-A1 | Novel Tyrosinase inhibitors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-01-14 | — | — | US | claimed |
| US-20100010049-A1 | Novel Tyrosinase inhibitors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-01-14 | — | — | US | disclosed |
| EP-2041095-A1 | NOVEL TYROSINASE INHIBITORS, THEIR PROCESS OF PREPARATION AND THEIR USE IN HUMAN MEDICINE AND IN COSMETICS | Galderma Research & Development (FR) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008006824-A1 | NOVEL TYROSINASE INHIBITORS, THEIR PROCESS OF PREPARATION AND THEIR USE IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-01-17 | — | — | WO | disclosed |
| WO-2007039821-A2 | NOVEL INHIBITORS OF TYROSINASE, THEIR METHOD OF PREPARATION AND THEIR USE IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010049-A1 | Novel Tyrosinase inhibitors and pharmaceutical/cosmetic applications thereof | TYR, MITF, MAOA | DBH 204/4885ALDH1A1 69/4885POLB 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.